HOME > > Products > Glac Single Strain Probiotic > B. animalis subsp. lactis CP-9
B. animalis subsp. lactis CP-9
Premium Probiotic Ingredient from Healthy Human Breast Milk
Bifidobacteria are key early colonizers of the human gut microbiota. CP-9, isolated from healthy human breast milk, is produced under our PRONEX® quality platform to ensure outstanding stability and performance. The strain has been evaluated across in-vitro, animal, and human studies, providing scientific support for roles in gut microbiota balance, metabolic health, immune balance, and skin wellness.
Core Advantages
Our value is to deliver safe, high-quality, and multifunctional probiotic ingredients.
- International safety framework: At the species level, B. animalis subsp. lactis is included on the EFSA QPS (Qualified Presumption of Safety) list. CP-9 is recognized for food use in select APAC markets, including Taiwan and Mainland China. A comprehensive CP-9 safety assessment was published in Journal of Food Science (2022), indicating no toxicity, no mutagenicity risk, and safety under prolonged intake.
- Robust scientific evidence: CP-9 is supported by 14+ patents (US/CN/TW) and 19+ SCI-indexed publications and academic reports. In 2023, CP-9 was a NutraIngredients Weight Management category finalist.
Advanced Quality & Identification (PRONEX®)
Our proprietary PRONEX® platform conducts full identity confirmation, purity verification, and functional characterization of CP-9. This technology underpins our quality commitment and ensures batch-to-batch consistency to the highest standards.
Excellent Stability & Application Potential
CP-9 shows strong acid and bile salt tolerance and intestinal adhesion, helping it transit the digestive tract and perform as intended. With appropriate packaging and storage, room-temperature shelf life is up to 36 months, facilitating versatile product development.
Research Areas & Applications
The multifunctionality of CP-9 makes it an ideal choice for diverse formulations.
- Gut health: Supports a balanced gut microbiota and digestive comfort.
- Metabolic health & weight management: Studies report associations with favorable trends in body composition as well as glycemic and lipid markers.
- Immune balance & antioxidation: In-vitro data indicate links to IL-10–related anti-inflammatory signaling and antioxidant capacity, supporting immune balance.
- Skin wellness: Supports comfort in sensitive skin and barrier function.
- Liquid-format patent application: Protected formulation (e.g., TWI800860) suitable for infants and adults preferring liquids; easy to incorporate into various foods.
Multi-strain Formulation Use
CP-9 can be combined with other strains to deliver comprehensive solutions, for example:
 |  |  |  |
| NosRelieve respiratory wellness support | FitStay weight management concepts | GlukoSolu glycemic/metabolic support | IntBrain cognitive & mood support |
Key Patent List
- TWI800740 – Composition for supporting bowel movements
- TWI572713 – Anti-obesity/weight-management applications
- TWI777475 – Support for glycemic metabolism
- TWI797881 – Healthy aging–related applications
- TWI786343 – Skin tone/brightening–related applications
- TWI777107 – Antioxidant-related applications
- TWI759126 – Anti-inflammatory–related applications
- TWI809634, TWI750716 – Skin comfort and inflammatory response–related applications
- TWI819926, TWI790820 – Pediatric care–related applications
📧 Contact us: glac@glac.com.tw
Further Reading:
- Glac Single Strain Probiotic Powder - Live Probiotic Powder
- PRONULIFE® Functional Probiotic Ingredients
References
- Bacteriostatic activities of lactic acid bacteria against extended-spectrum β-lactamase(ESBL)-producing Escherichia coli. Basic Clin Pharmacol Toxicol. 2019;125(Suppl. 6):3-4.
- Bacteriostatic abilities of viable and heat-killed lactic acid bacteria against group B Streptococcus. Basic Clin Pharmacol Toxicol. 2019;125(Suppl. 6):12-13.
- Assessment of bacteriostatic activities of viable and non-viable lactic acid bacteria against methicillin-resistant Staphylococcus aureus. Basic Clin Pharmacol Toxicol. 2019;125(Suppl. 6):14-15.
- Antibacterial activity of viable and heat-killed
probiotic strains against oral pathogens. Lett Appl Microbiol. 2020 Apr;70(4):310-317.
